Ligand Pharmaceuticals (NASDAQ: LGND) announced today that the FDA has granted accelerated approval of GlaxoSmithKline's PROMACTA for the treatment of ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE